Genomic Health Reaches New 52-Week High (GHDX)
NEW YORK (
) --
(Nasdaq:
) hit a new 52-week high Friday as it is currently trading at $29.36, above its previous 52-week high of $29.34 with 100,004 shares traded as of 12:49 p.m. ET. Average volume has been 182,100 shares over the past 30 days.
Genomic Health has a market cap of $785.7 million and is part of the
sector and
industry. Shares are up 12.8% year to date as of the close of trading on Thursday.
Genomic Health, Inc., a molecular diagnostics company, focuses on the development and global commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. The company has a P/E ratio of 129.2, above the average health services industry P/E ratio of 120.9 and above the S&P 500 P/E ratio of 17.7.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Genomic Health as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. You can view the full
.
See all
52-week high stocks
or get investment ideas from our
.
null
